Condition: glp1 Agonist · Gene Expression · Skin Laxity · Sponsor: Cytrellis Biosystems, Inc.
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity
This description comes directly from the study's public registry record.
Karyn Siemasko, PhD · 949-394-0585 · ksiemasko@cytrellis.com
Delia Khayat, PharmD · 305-484-4948 · dkhayat@cytrellis.com
Always discuss trial participation with your own doctor first.
| Tri Valley Plastic Surgery | Dublin, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07224880